Ionis press release
Web21 jun. 2024 · Based on the 35-week interim trial results, the companies will seek regulatory approval for eplontersen and plan to file a new drug application with the US Food and … Web13 jul. 2024 · Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics. - Bicycle to receive a total …
Ionis press release
Did you know?
Web13 nov. 2024 · About Ionis Pharmaceuticals, Inc. For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of … Web9 nov. 2024 · For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing the standards of care with its novel antisense …
Web1 uur geleden · LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, April 14, 2024 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced a presentation at the 2024 American Association for ... Web28 feb. 2024 · Ionis announced FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS Mar 07, 2024 Ionis announces FDA … Ionis Partner Biogen Announces That Results From Phase 3 Valor Study and … Ionis Announces Positive Data for Etesian Phase 2B Study of ANTISENSE … Ionis Announces Publication of Positive Phase 2 Data for Donidalorsen in New … Ionis' Forward-looking Statement. This press release includes forward-looking … These statements are based on our current beliefs and expectations and speak only … press release PDF Version. Ionis to present at RBC Capital Markets Global … Pfizer and Ionis Announce Discontinuation of Vupanorsen Clinical Development … press release PDF Version. Ionis to present at 40th Annual J.P. Morgan Healthcare …
Web11 jul. 2024 · This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of Ionis' technologies, IONIS-FB … Web29 mrt. 2024 · This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of Ionis' technologies, IONIS-MAPT Rx and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and …
Web29 mrt. 2024 · As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused every moment on advancing drug discovery, development, and …
Web7 mrt. 2024 · CARLSBAD, Calif., March 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug... diana \u0026 associates rice lake wiWeb7 sep. 2024 · In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals® is a trademark ... diana twardy strasslachWeb26 jul. 2024 · CARLSBAD, Calif., July 26, 2024 /PRNewswire/ -- IonisPharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration(FDA) has accepted a New Drug Application (NDA) for tofersen, an investigational antisensemedicine for the treatment of superoxide dismutase1 amyotrophiclateral sclerosis (SOD1-ALS). diana tx land for saleWeb20 jul. 2024 · CARLSBAD, Calif., July 20, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Novartis has completed patient enrollment of the pivotal Phase 3 Lp (a) HORIZON... citat konfirmationWeb23 mrt. 2024 · About Ionis Pharmaceuticals, Inc. For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of … citat leadershipdiana tx to henderson txWeb6 dec. 2024 · About Ionis Pharmaceuticals, Inc. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, … citat madicken